EUCTR2017-004168-36-GB进行中（未招募）1 期
A phase II study of pembrolizumab in patients with advanced gynaecological clear cell cancer - PEACOCC
niversity College London0 个研究点目标入组 48 人开始时间: 2019年6月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Histological diagnosis of advanced gynaecological cancer including ovarian (including primary peritoneal and fallopian tube), endometrial, vaginal, vulval or cervical cancer.
- •2. Be willing and able to provide written informed consent/assent for the trial.
- •3. Age =18 years.
- •4. Patient must have at least one measurable lesion according to RECIST v1.1 in addition to a separate biopsiable lesion. Measurable lesions should be outside any prior radiation field unless progression has occurred at that site.
- •5. Have measurable disease according to RECIST v1.1.
- •6. Evidence of radiological disease progression.
- •7. Patient is willing to provide archival tissue.
- •8. ECOG Performance Status 0 or 1.
- •9. Patient has a life expectancy of at least 4 months from consent.
- •10. Received = 1 line of prior chemotherapy.
- •11. Demonstrate adequate organ function.
- •12. For patients of childbearing potential, negative urine or serum pregnancy test prior to receiving the first dose of study medication.
- •13. Patients of childbearing potential must be willing to use a highly effective method of contraception for the study duration required.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 0
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1. Patient is currently participating in and receiving other study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- •2. Prior anti-cancer monoclonal antibody (mAb), chemotherapy or targeted small molecule therapy within 4 weeks prior to study treatment Day 1 or who has not recovered (i.e., = Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
- •3. Radiation therapy within 2 weeks prior to starting study treatment.
- •4. Prior therapy with an anti-PD-1, anti-PD-L1 or anti-PD-L2 agent.
- •5. Known diagnosis of immunodeficiency or is receiving systemic steroid therapy at doses > 10mg prednisolone daily or equivalent or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- •6. Has a known history of active bacillus tuberculosis (TB).
- •7. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] detected) infection.
- •8. Known history of Human Immunodeficiency Virus (HIV) (HIV type 1/2 antibodies).
- •9. Known hypersensitivity to pembrolizumab or any of its excipients.
- •10. Known additional malignancy that is progressing or requires active treatment. If there is a history of a second malignancy and there is doubt regarding the aetiology of progressive disease, then a biopsy is required to determine the diagnosis.
- •11. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •12. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids (at a dose >10mg predisolone daily or equivalent) or immunosuppressive drugs).
- •13. Corrected serum calcium of grade 1 hypercaelcemia (>2.9 mmol/L) despite maximal antihypercalcaemic therapy.
- •14. Has a known history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
- •15. Newly diagnosed venous thromboembolic event (eg pulmonary embolism, deep vein thrombosis DVT), unless patient has received at least 14 days of therapeutic dose anticoagulation for a new thromboembolic event and is suitable for continued therapeutic anticoagulation during trial participation.
- •16. History of arterial thrombosis (excluding the pulmonary artery), within 12 months prior to registration (if beyond 12 months prior to registration, patient may be included providing they have fully recovered clinically).
- •17. Active infection requiring systemic therapy (for example antibiotics, antivirals, antifungals).
- •18. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient’s participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
- •19. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- •20. Pregnant or breastfeeding.
- •21. Has received a live vaccine within 30 days prior to the planned start of trial treatment.
- •22. Has been hospitalised for bowel obstruction within 4 weeks prior to registration.
- •23. Current abdominal/pelvic fistulation.
研究者
相似试验
进行中（未招募）
1 期
A phase II study of pembrolizumab in patients with malignant peripheral nerve sheath tumor (MPNST), not eligible for curative surgeryMalignant peripheral nerve sheath tumor (MPNST), not eligible for curative surgeryEUCTR2015-004747-39-NOOslo University Hospital18
进行中（未招募）
1 期
A phase II trial of MK-3475 in patients with non-small cell lung cancer with a performance status of 2non small cell lung cancer (NSCLC)MedDRA version: 18.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-002241-55-GBniversity of Birmingham
招募中
不适用
Phase II study of pembrolizumab in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine: integration of molecular subtypes through integrative genomic analysis.NeoplasmsKCT0003562Samsung Medical Center40
进行中（未招募）
2 期
A phase 2 study of pembrolizumab in combination with olaparib in patients with cervical cancer previously treated with platinum-based chemotherapyrecurrent or metastatic cervical cancercervical cancer ,Pembrolizumab,OlaparibJPRN-jRCT2031210096Hasegawa Kosei28
进行中（未招募）
1 期
PROMO: A phase II study of Pembrolizumab in patients with Relapsed Or Metastatic Osteosarcoma not eligible for curative surgeryEUCTR2016-001676-29-ITOSLO UNIVERSITETSSYKEHUS HF25